Your session is about to expire
← Back to Search
PT2385 for Renal Cell Carcinoma
Study Summary
This trial will study the effects of PT2385 on VHL-associated ccRCC tumors. The primary goal is to measure the overall response rate.
- Von Hippel-Lindau Syndrome
- Von Hippel-Lindau Disease
- Renal Cell Carcinoma
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have received radiation or other cancer treatments for a type of kidney cancer called ccRCC.You have been diagnosed with von Hippel Lindau disease because of a specific genetic change in the VHL gene.You have had another type of cancer, except for certain skin or cervical cancers, that has been treated and didn't come back for at least 2 years.You had radiation treatment to a different site than the kidney cancer within the last 4 weeks, or you haven't fully recovered from any side effects of the treatment.You have kidney cancer, and the largest tumor is no bigger than 3.0 cm, as seen on scans. You may also have other VHL-related growths in different parts of your body.You have had cancer that has spread to other parts of your body.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- Group 1: PT2385 Tablets
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
How many people are participating in this clinical experiment?
"At this time, enrolment for the trial is temporarily closed. The posting date was April 24th 2017 and it was last modified on August 10th 2022. If you're looking to join a study, 3966 studies are currently accepting patients with von hippel-lindau disease while 3 trials are recruiting participants to test PT2385 Tablets."
Is this experimental trial a pioneering endeavor?
"Peloton Therapeutics, Inc. first initiated research on PT2385 Tablets in 2014 and the drug was granted Phase 1 approval following a study involving 110 patients. Presently, 3 studies of this medication are underway across 22 cities within one nation."
Is this study currently enlisting participants?
"Records on clinicaltrials.gov demonstrate that this trial has ceased recruitment, as the last update was made in August of 2022 and it launched back in April 2017. Despite no longer accepting participants, there are currently 3969 other trials recruiting patients worldwide."
Has the FDA granted clearance to PT2385 Tablets?
"Leveraging our proprietary safety assessment scale, PT2385 Tablets have been tentatively granted a score of 2. This is because there has only been limited evidence that attests to their security and none yet indicating efficacy."
Are there any documented precedents of PT2385 Tablets being tested in clinical trials?
"Presently, there are three ongoing trials for PT2385 Tablets and none have reached Phase 3. Trials taking place in Bethesda, Maryland serve as the epicentre of these investigations, though 27 other sites throughout America are also running studies on this medication."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger